1. Introduction {#s0005}
===============

Congenital heart disease (CHD) is one of most common congenital anomalies. CHD is a major cause of fetal loss and death in newborns less than one year of age all over the world. Approximately, CHD accounts for 28% of the major congenital anomalies ([@bb0200]). The generally accepted prevalence of CHD was about 8 per 1000 live births, which poses a serious challenge to healthcare ([@bb0015]). Remarkable progresses have been achieved in CHD diagnosis and cardiac surgery during the past decades, resulting in an increased survival rate of neonates with CHD ([@bb0055]). However, more patients with CHD have grown up who comprised of a special population: patients with grown-up congenital heart disease (GUCH) ([@bb0075; @bb0200]). It was reported that the prevalence of patients with GUCH was estimated to be 4 per 1000 adults. Long-term medical care and related resource cost are needed for patients with GUCH, and rapidly increase healthcare burden.

Since more GUCH patients survive, more are now in childbearing age. Thus, it is very important to characterize the etiology of congenital heart disease, which has not been well understood yet. Several classic studies including the Baltimore--Washington Infant Study have indicated that the cause of CHD was multifactorial, and both genetic background and environmental factors may play important roles in the development of CHD ([@bb0150; @bb0175]). Importantly, due to the advances in molecular techniques, accumulating evidences have suggested that genetic factors were dominant ([@bb0030]). It was known that a large proportion of CHDs were characterized with aneuploidy or abnormal chromosomal number ([@bb0020; @bb0145]). About 50% of children who were born with Trisomy 21 have atrial and ventricular septal defects or atrioventricular canal lesion. With completion of the Human Genome Project, associations between single gene mutations and CHD have also been extensively studied. It has been reported that the mutations in single genes including *TBX5*, *JAG1*, *NKX2.5* and *GATA4* have been associated with the development of CHD ([@bb0010; @bb0135; @bb0160; @bb0250]).

The association between folic acid metabolism and the development of CHD has been explored recently. Maternal supplement of folic acid has been proved to reduce the incidence of CHD as well as other congenital heart disease ([@bb0190]). Single nucleotide polymorphisms of many genes involved in the folate pathway have been identified to affect the function of the genes or folic acid metabolism and thus increase the risk of CHD ([@bb0115; @bb0170]). The flavin adenine dinucleotide-dependent enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is required for the remethylation of homocysteine to methionine ([@bb0185]). Hyperhomocysteinemia was believed to be a high risk for the development of heart defects ([@bb0215; @bb0210]). Elevating the level of 5-methyltetrahydrofolate, a major circulating folic acid, prevented CHD by reducing maternal homocysteine plasma level ([@bb0080]). Therefore, the polymorphisms of *MTHFR* may be closely related to the risk of CHD. It was reported that two *MTHFR* SNPs including *MTHFR* C677T (p.Ala222Val, ID: rs1801133) and *MTHFR* A1298C (p.Glu429Ala, rs1801131) were potentially associated with CHD ([@bb0205]). The amino acid transition in *MTHFR* C677T (Ala-Val) has resulted in a thermolabile protein associated with reduced enzyme activity in vivo, which may increase plasma homocysteine level ([@bb0065]). The *MTHFR* A1298 C has also been reported to moderately reduce MTHFR activity in vivo ([@bb0225]).

To date, a large number of studies regarding the associations between *MTHFR* gene polymorphisms and risk of CHD have been published. However, the results of these studies were confounding and inconsistent. Herein, we performed a meta-analysis of all published studies until January 2013 to investigate the association between the two SNPs (*MTHFR* 677CT and *MTHFR* 1298AC) and CHD patients and their mothers.

2. Materials and methods {#s0010}
========================

2.1. Literature and search strategy {#s0015}
-----------------------------------

The PubMed, Embase, Web of knowledge and CNKI (China National Knowledge Infrastructure) database searches were performed to identify all the eligible papers. The search terms were used as the following: (MTHFR or methylenetetrahydrofolate reductase or folic acid) and (variant or polymorphism or SNP) and (congenital heart disease or heart defect or CHD or congenital anomalies). The publication languages were restricted to English and Chinese. Moreover, potentially relevant studies were evaluated by reviewing the titles and abstracts, and studies matching the criteria were carefully retrieved. If more than one study was published using the same data, only the study with a larger population was included. The literature search was updated on January, 31, 2013.

2.2. Inclusion criteria and data extraction {#s0020}
-------------------------------------------

The eligible studies should meet the following inclusion criteria: (1) Investigation of association between the MTHFR polymorphisms (including C677T or A1298C or both) and congenital heart disease; (2) a case--control study; (3) providing sufficient data on genotype frequencies of the MTHFR C677T and/or A1298C polymorphisms and sufficient data for calculation of an odd ratio (OR) with 95% confidence interval (CI). The exclusion criteria were as follows: (1) reviews, case report, editorial or comment; (2) a duplicated study; (3) studies providing insufficient data or data in poor quality; and (4) studies without control. Based on the inclusion and exclusion criteria, data extraction from each study was performed by two authors (Wang, Hou) independently to ensure that the data extraction were accurate. The following information was extracted from each study: (1) name of the first author; (2) year of publication; (3) country of origin; (4) ethnicity of the study population; (5) source of controls (population based or hospital based); (6) sample size of case and controls; (7) types of congenital heart disease; (8) genotype distributions in cases and controls; and (9) whether population involved in the study was in Hardy--Weinberg equilibrium (HWE).

2.3. Statistical analysis {#s0025}
-------------------------

Meta-analysis was performed to evaluate the association between MTHFR polymorphisms and risk of developing CHD. Firstly, crude ORs with 95% CIs were calculated to assess the strength of the correlation between the MTHFR C677T/A1298C polymorphisms (including maternal and fetal) and risk of CHD. Pooled ORs and 95% CIs were calculated for the multiplicative, co-dominant, dominant, and recessive genetic models respectively. The significances of pooled ORs were analyzed by Z tests, and the criteria for statistically significant were p \< 0.05. A Q test was conducted to determine the possible heterogeneity, and p \< 0.10 or I \> 50% indicated an obvious heterogeneity. Pooled ORs (95% CI) were calculated by random effects model (DerSimonian--Laird method) or fix effects model (Mantel--Haenszel method). Subgroup analysis was performed by ethnicity, types of CHD, source of controls and sample size (n \< 100 vs. n \> 100). Sensitivity analysis were performed to evaluate the stability of the results by removing one case--control study each time to assess the influence of the individual data on pooled ORs. Begg\'s funnel plot was generated to indicate the possible publication bias. Moreover, the Egger quantitative tests were also performed, and p \< 0.05 was considered statistically significant. To obtain reliable data, two authors (Wang, Hou) have performed the statistical analysis independently by using the same data and the programs. Data analyses were performed using STATA version 12 (Stata Corporation, College Station, Texas, USA).

3. Results {#s0030}
==========

3.1. Characteristics of the studies included {#s0035}
--------------------------------------------

Totally, we have identified 288 potentially relevant studies by employing the search strategy described above. Based on obvious irrelevance to MTHFR and CHD in titles, 248 papers from the 288 potentially relevant papers were excluded. After reading the abstracts of the remaining 40 studies, 7 studies were further excluded, as 6 studies were reviews and one study was a duplicated study. To further polish target studies, the remaining studies were reviewed in full text. Of these, 9 studies were excluded, due to insufficient data, data with poor quality or papers without control. After careful screening, 24 eligible studies were finally included in this meta-analysis ([@bb0005; @bb0025; @bb0035; @bb0040; @bb0050; @bb0045; @bb0060; @bb0070; @bb0085; @bb0105; @bb0090; @bb0095; @bb0110; @bb0140; @bb0155; @bb0165; @bb0180; @bb0195; @bb0205; @bb0220; @bb0230; @bb0235; @bb0240; @bb0255]). The search strategy and inclusion/exclusion of studies were shown in a flow chart ([Fig. 1](#f0005){ref-type="fig"}). Among these studies, fourteen studies investigated the maternal MTHFR C677T polymorphism with 1745 cases and 2044 controls and nineteen studies investigated the fetal MTHFR C677T polymorphism with 2697 cases and 3434 controls. In addition, there were 4 studies investigating maternal MTHFR A1298C polymorphism with 432 cases and 532 controls and 5 studies investigating fetal MTHFR A1298C polymorphism with 945 cases and 1074 controls. Concerning Hardy--Weinberg equilibrium, 3 studies were not conformed to HWE. In these papers, 9 studies included both maternal and fetal MTHFR polymorphisms and 5 studies included both MTHFR C677T and A1298C polymorphisms. Moreover, 11 studies were performed in Caucasian and 12 studies were performed in Asian. The general characteristics of the studies included were listed in [Table 1](#t0005){ref-type="table"}. The genotype and allele distributions of maternal C677T and A1298C polymorphisms in all the studies included were shown in [Table 2](#t0010){ref-type="table"}. For the fetal polymorphisms, the genotype and allele frequencies of C677T and A1298C were shown in [Table 3](#t0025){ref-type="table"}.

3.2. Quantitative data analysis {#s0040}
-------------------------------

For the maternal MTHFR C677T polymorphism, the results indicated no statistically significant association between the polymorphism and the susceptibility to CHD in all genetic models except for recessive model and co-dominant model (T vs. C: OR = 1.103, 95% CI 0.999--1.218; TT vs. CC: OR = 1.254, 95% CI 1.012--1.553; TT + CT vs. CC: 1.105, 95% CI 0.958--1.275; TT vs. TC + CC: OR = 1.235, 95% CI 1.024--1.489) ([Table 4](#t0030){ref-type="table"} [Fig. 2](#f0010){ref-type="fig"}). In the subgroup analysis by ethnicity, no significant association was observed in Asian population in all genetic models except for recessive model (T vs. C: OR = 1.204, 95% CI 0.973--1.490; TT vs. CC: OR = 1.454, 95% CI 0.921--2.295; TT + CT vs. CC: OR = 1.170, 95% CI 0.802--1.707; TT vs. TC + CC: OR = 1.431, 95% CI 1.011--2.024) ([Table 4](#t0030){ref-type="table"}). No association was detected in Caucasians in all genetic models. In the stratified analysis by types of CHD, there was a significant association between C667T and ASD/PDA, however, the results were not reliable because only one study was performed in ASD/PDA patients ([Table 4](#t0030){ref-type="table"}). In the subgroup of source of control, association was only observed in the recessive model of hospital based control subgroup (TT vs. TC + CC: OR = 1.550, 95% CI 1.106--2.170) ([Table 4](#t0030){ref-type="table"}). In the sample size subgroup analysis, there was no significant association between CHD and maternal C677T in all genetic models of large sample studies. However, we have observed a significant association in co-dominant model and recessive model with small sample studies ([Table 4](#t0030){ref-type="table"}).

For the fetal MTHFR C667T polymorphism, the overall results suggested a significant association of polymorphism with CHD susceptibility (T vs. C: OR = 1.271, 95% CI 1.178--1.372; TT vs. CC: OR = 1.610, 95% CI 1.374--1.885; TT + CT vs. CC: OR = 1.258, 95% CI 1.120--1.414; TT vs. TC + CC: OR = 1.565, 95% CI 1.370--1.788) ([Table 5](#t0015){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}). In the subgroup by ethnicity, fetal MTHFR C677T was associated with CHD in Asian populations for all genetic models, however, no significant association was found in Caucasian ([Table 5](#t0015){ref-type="table"}). In the stratified analysis by types of CHD, significant associations were detected between fetal MTHFR C677T and all types of CHD for all genetic models ([Table 5](#t0015){ref-type="table"}). Similar significant association was also observed in CD and ASD/PDA, however, the positive result in CD was not reliable because it was derived from one study. Interestingly, a significant association was observed in hospital based control subgroup rather than in population based control subgroup. By considering sample size, significant results were also found in all genetic models in both small and large sample subgroups ([Table 5](#t0015){ref-type="table"}).

For MTHFR A1298C polymorphism, the results showed no significant association between this polymorphism and CHD risk in either maternal or fetal groups (maternal: T vs. A: OR = 1.043, 95% CI 0.855--1.271; CC vs. AA OR = 1.109, 95% CI 0.692--1.775; CC + AC vs. AA: OR = 1.108, 95% CI 0.856--1.435; CC vs. AC + AA: OR = 0.735, 95% CI 0.467--1.157; fetal: C vs. A OR = 0.938, 95% CI 0.812--1.083; CC vs. AA: OR = 1.058, 95% CI 0.719--1.558; CC + AC vs. AA: OR = 0.871, 95% CI 0.728--1.042; CC vs. AC + AA: OR = 1.184, 95% CI 0.815--1.721). In the subgroup analysis of either maternal or fetal polymorphisms, there was no statistically significant association in each subgroup by ethnicity, types of CHD, source of controls and sample size under all genetic models ([Table 6](#t0020){ref-type="table"}).

3.3. Source of heterogeneity {#s0045}
----------------------------

As shown in [Table 4](#t0030){ref-type="table"}, heterogeneity between studies was significant (p \< 0.10) under additive, and recessive genetic models for maternal MTHFR C677T. Moreover, evidence for heterogeneity between studies was also found in all genetic models for fetal MTHFR C677T. For the MTHFR A1298C polymorphism, significant heterogeneity was only found in recessive model of maternal polymorphism. No evidence for heterogeneity between studies was detected for maternal MTHFR C677T in the co-dominant and dominant models, for maternal and fetal MTHFR A1298C under all genetic models except for maternal recessive model.

3.4. Sensitivity analysis {#s0050}
-------------------------

In the sensitivity analysis, the overall association between the maternal MTHFR C677T genotype and CHD was not substantially changed by excluding one study at a time (data not shown). Similar results were also found in fetal MTHFR C677T, maternal and fetal MTHFR A1298C.

3.5. Potential publication bias {#s0055}
-------------------------------

Except for dominant model of fetal MTHFR C677T and co-dominant model of maternal A1298C polymorphisms, no publication bias could be detected by employing Egger\'s test for studies on maternal MTHFR C677T polymorphism (T vs. C: p = 0.647; TT vs. CC: p = 0.324; TT + CT vs. CC p = 0.533; TT vs. TC + CC: p = 0.269); fetal MTHFR C677T polymorphism (T vs. C: p = 0.077; TT vs. CC: p = 0.110; TT vs. TC + CC: p = 0.057); maternal MTHFR A1298C polymorphism (C vs. A: p = 0.882; CC + AC vs. AA: p = 0.330; CC vs. AC + AA: p = 0.107); and fetal MTHFR A1298C polymorphism (C vs. A: p = 0.493; CC vs. AA: p = 0.576; CC + AC vs. AA: p = 0.576; CC vs. AC + AA: p = 0.576). The results of Egger\'s test suggested publication bias in dominant model of fetal MTHFR C677T polymorphism (TT + CT vs. CC: p = 0.006) and co-dominant model of maternal A1298C polymorphism (CC vs. AA: p = 0.049). The Begg\'s tests of corresponding genetic models in forest plots were shown in [Figs. 2 and 3](#f0010 f0015){ref-type="fig"}.

4. Discussion {#s0060}
=============

To date, it is known that genetic and environmental risks may be the causes of congenital heart diseases. Importantly, numerous studies have suggested the role of folic acid metabolism in the CHD development ([@bb0185]). MTHFR is a key enzyme in folic acid conversion process, and its activity may be related with a variety of diseases including CHD ([@bb0100; @bb0120]). It was reported that the C677T mutation of MTHFR could render the enzyme thermolabile with approximately 50% reduced activity and increased plasma homocysteine concentrations ([@bb0065]). Therefore, the variants of the MTHFR gene may modulate the activity of MTHFR and may be an important determinant of CHD development. Several studies have reported the potential association between MTHFR polymorphisms (C677T and A1298C) and CHD, however, the results were not consistent ([@bb0005; @bb0035]). Our current comprehensive meta-analysis could better evaluate the association between MTHFR C677T/A1298C and susceptibility of CHD. Two studies have performed meta-analysis in association between MTHFR C677T polymorphism and CHD two years ago ([@bb0130; @bb0245]). However, the MTHFR A1298C polymorphism was not analyzed in either of the two studies. Moreover, subgroup analysis based methods were not employed in previous studies. We have analyzed the association between MTHFR polymorphisms and CHD by multiple methods in all genetic models and included more recent studies. To our knowledge, this is the first meta-analysis on association between MTHFR polymorphisms and CHD including both C677T and A1298C.

For the MTHFR C677T polymorphism, most studies have indicated that maternal C677T was not a strong risk of CHD, however, some reports have suggested its potential role in CHD development. In our finding, no statistically significant difference was detected in genotype or allele frequencies of MTHFR C677T polymorphism in the mothers of CHD patients compared with controls. Only marginal association between maternal C677T polymorphism and CHD was found in recessive model. The finding was consistent with the previous studies involving both maternal and fetal C677T polymorphism. Particularly, we found a significant association between maternal C677T and CHD in recessive genetic models of Asian subgroup, however, similar result was not observed in Caucasian. This discrepancy of association between Asian and Caucasian groups may be attributed to the different genetic background and environmental factors.

Our results have indicated that fetal MTHFR C677T polymorphism was significantly associated with CHD in all genetic models. It was evident that fetal MTHFR C677T polymorphism was an important risk in the development of CHD. To explain the results, we speculated that decreased fetal MTHFR enzyme activity may result in a local hyperhomocystein environment, in which the heart could not develop normally ([@bb0125]). These evidences have supported the viewpoint that fetal MTHFR C677T polymorphism was more important than maternal MTHFR C677T polymorphism, and concentration of homocystein in fetus may influence heart development rather than maternal homocystein concentration. In addition, we found that fetal MTHFR C677T was significantly associated with CHD in Asian, while no statistically significant association was found in Caucasian population. Consistent with the result from recessive model of maternal analysis, the fetal MTHFR C677T was more likely to be associated with CHD in Asian than Caucasian. The results have validated the notion that MTHFR C667T may be in combination with other genetic background and environment factors to affect the fetal heart development. By considering the source of controls, the association between MTHFR C667T polymorphism and CHD was significant in hospital based control group, though, not significant in population based control. The confounding results from two subgroups categorized by source of control have indicated that hospital based and population based control was not homogenous in this study. We believe that the comparability between cases and controls contributes to the disagreement of these two subgroups.

For the MTHFR A1298C polymorphism, we found no statistically significant association between this polymorphism and CHD either in maternal or fetal analysis. Our finding has demonstrated that MTHFR A1298C may not be a risk of congenital heart disease development. However, some studies indicated that the interaction between MTHFR 1298 C allele and folic acid supplement increased the risk of having a child with CHD ([@bb0205]). Considering that minimal eligible studies included in our meta-analysis, this result should be validated with more studied and large pooled samples in future. In subgroup analysis by ethnicity, only one study was performed in Asian population to investigate fetal A1298C polymorphism and four studies were performed in Caucasian population. Because of the importance of MTHFR polymorphisms in Asian CHD development, we suggest that more studies investigating association between A1298C polymorphism and CHD be performed in Asian population.

5. Potential study limitations {#s0065}
==============================

Although we made these findings in this meta-analysis, there were several limitations. First, our study was mainly based on unadjusted odd ratios, and the potential covariates including gender, age, vitamin supplement, smoking or other environmental factors, which might influence the final results, were unable to control. Second, significant heterogeneity in the study was presented in overall and subgroup analysis. We have investigated the study heterogeneity including geographic region, ethnicity, and source of control. However, none of them was identified as the potential source of heterogeneity between studies by meta-regression (data not shown). We estimated that other unknown confounding factors may help explain the between-study heterogeneity. Third, it was known that there were several subtypes of congenital heart diseases. However, only a few studies included in our meta-analysis have classified their cases by types of CHD. To analyze this issue, we need more studies involving CHD cases with clear subtypes.

6. Conclusion {#s0070}
=============

Despite the limitations mentioned above, the present study has demonstrated that the fetal MTHFR C677T polymorphism is an important risk of developing congenital heart diseases. Our findings also suggest that MTHFR A1298C polymorphism does not increase the susceptibility to CHD. Interestingly, we found that fetal MTHFR C677T polymorphism more likely affects Asian fetus than Caucasian fetus in the development of CHD.
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![Forest plot of meta-analysis of association between maternal MTHFR C677T polymorphism and CHD risk and funnel plot analysis on the detection of publication bias. (A) Meta-analysis in a random effects model for C vs. T (additive model); (B) meta-analysis in a random effects model for CC vs. TT (co-dominant model); (C) meta-analysis in a random effects model for TT + CT vs. CC (dominant model); (D) meta-analysis in a random effects model for TT vs. CC + CT (recessive model). Left panel: forest plot analysis, each study is shown by the point of estimating the OR and 95% CIs for corresponding ORs were shown by extending lines; right panel: funnel plot analysis, each point represents an individual study. LogOR, natural logarithm of OR, perpendicular line denotes the mean effect size.](gr2){#f0010}

![Forest plot of meta-analysis of association between fetal MTHFR C677T polymorphism and CHD risk and funnel plot analysis on the detection of publication bias. (A) Meta-analysis in a random effects model for C vs. T (additive model); (B) meta-analysis in a random effects model for CC vs. TT (co-dominant model); (C) meta-analysis in a random effects model for TT + CT vs. CC (dominant model); (D) meta-analysis in a random effects model for TT vs. CC + CT (recessive model). Left panel: forest plot analysis, each study is shown by the point of estimating the OR and 95% CIs for corresponding ORs were shown by extending lines; right panel: funnel plot analysis, each point represents an individual study. LogOR, natural logarithm of OR, perpendicular line denotes the mean effect size.](gr3){#f0015}

###### 

Characteristics of the studies included on associations between MTHFR C677T/A1298C polymorphisms and congenital heart disease.

  First author                       Year   Country         Ethnicity   Source of controls   Genotyping method   Types of CHD   Maternal or fetal   SNP sites   HWE   
  ---------------------------------- ------ --------------- ----------- -------------------- ------------------- -------------- ------------------- ----------- ----- -----
  Balderrabano-Saucedo ([@bb0005])   2013   Mexico          Caucasian   HB                   RFLP                All types      Maternal            Yes               Yes
  Božovic ([@bb0025])                2011   Croatia         Caucasian   PB                   RFLP                All types      Both                Yes         Yes   Yes
  Hobbs ([@bb0060])                  2010   United States   Caucasian   PB                   TaqMan              All types      Maternal            Yes               Yes
  García-Fragoso ([@bb0040])         2010   Puerto Rico     Caucasian   HB                   RFLP                All types      Both                Yes               No
  Xu ([@bb0235])                     2010   Chinese         Asian       HB                   RFLP                All types      Fetal               Yes         Yes   Yes
  Li ([@bb0095])                     2009   Chinese         Asian       HB                   RFLP                All types      Fetal               Yes               Yes
  van Driel ([@bb0205])              2008   Netherlands     Caucasian   PB                   RFLP                All types      Both                Yes         Yes   Yes
  Wintner ([@bb0230])                2007   Austria         Caucasian   HB                   Microarray          All types      Maternal            Yes               Yes
  van Beynum ([@bb0195])             2006   Netherlands     Caucasian   PB                   RFLP                All types      Maternal            Yes               Yes
  Galdieri ([@bb0035])               2007   Brazil          Caucasian   HB                   RFLP                All types      Both                Yes         Yes   Yes
  Zhu ([@bb0255])                    2006   Chinese         Asian       NA                   RFLP                ASD/PDA        Both                Yes               Yes
  Lee ([@bb0085])                    2005   Chinese         Asian       HB                   DHPLC               All types      Fetal               Yes               Yes
  Shaw ([@bb0165])                   2005   United States   Caucasian   PB                   Hybridization       All types      Fetal               Yes               Yes
  Storti ([@bb0180])                 2003   Italy           Caucasian   HB                   RFLP                CD             Both                Yes         Yes   Yes
  Junker ([@bb0070])                 2001   Germany         Caucasian   NA                   NA                  All types      Fetal               Yes               Yes
  Sanchez-Urbina ([@bb0155])         2012   Mexico          Caucasian   PB                   RFLP                All types      Both                Yes               No
  Yan ([@bb0240])                    2003   Chinese         Asian       HB                   RFLP                All types      Fetal               Yes               Yes
  Gong ([@bb0045])                   2012   Chinese         Asian       HB                   MassArray           CD             Fetal               Yes               Yes
  Wang ([@bb0220])                   2004   Chinese         Asian       HB                   RFLP                All types      Both                Yes               No
  Peng ([@bb0140])                   2009   Chinese         Asian       HB                   DHPLC               All types      Maternal            Yes               Yes
  Li ([@bb0090])                     2009   Chinese         Asian       HB                   RFLP                All types      Fetal               Yes               Yes
  Gong ([@bb0050])                   2009   Chinese         Asian       HB                   RFLP                All types      Fetal               Yes               Yes
  Liu ([@bb0110])                    2005   Chinese         Asian       HB                   RFLP                CD             Fetal               Yes               Yes
  Li ([@bb0105])                     2005   Chinese         Asian       PB                   RFLP                All types      Both                Yes               Yes

Abbreviations: HWE, Hardy--Weinberg equilibrium; NA, not available; RFLP, restriction fragment length polymorphism; DHPLC, denaturing high performance liquid chromatography; CD, conotruncal heart defects; ASD, atrial septal defect; PDA, patent ductus arteriosus; PB, population-based; HB, hospital-based.

###### 

Genotype and allele distributions of maternal MTHFR C677T/A1298C polymorphisms in case-control studies included.

  Study                         Sample size case/control   Genotype distribution   Allele distribution                                                                                                    
  ----------------------------- -------------------------- ----------------------- --------------------- ------------- -------------- ------------- -------------- ------------- -------------- --------- ---------
  *MTHFR* 677CT polymorphism                               CC                      CT                    TT            CT + TT        CT            TT             CT + TT       C              T         CC
  Balderrabano-Saucedo          31/62                      7 (22.6%)               12 (38.7%)            12 (38.7%)    24 (77.4%)     24 (38.7%)    31 (50%)       7 (11.3%)     38 (61.3%)     26/79     36/45
  Božovic                       52/55                      26 (50%)                20 (38%)              6 (12%)       26 (50%)       19 (35%)      28 (51%)       8 (14%)       36 (65%)       72/66     32/44
  Hobbs                         572/363                    285 (51.5%)             203 (36.7%)           65 (11.8%)    268 (48.5%)    191 (53.7%)   128 (36%)      37 (10.4%)    165 (46.4%)    773/510   333/202
  García-Fragoso                27/220                     10 (37%)                11 (41%)              6 (22%)       17 (63%)       84 (38%)      115 (52%)      21 (10%)      136 (62%)      31/283    23/157
  van Driel                     230/251                    91 (40%)                117 (51%)             22 (9%)       139 (60%)      111 (44%)     104 (42%)      36 (14%)      140 (56%)      299/326   161/176
  Wintner                       31/31                      17 (54.84%)             11 (35.48%)           3 (9.68%)     14 (45.16%)    10 (32.26%)   17 (54.84%)    4 (12.9%)     21 (67.74%)    45/37     17/25
  Van Beynum                    158/261                    72 (45.6%)              68 (43%)              18 (11.4%)    86 (54.4%)     131 (50.2%)   107 (41%)      23 (8.8%)     130 (49.8%)    212/369   104/153
  Galdieri                      47/26                      27 (57.45%)             15 (31.91%)           5 (10.64%)    20 (42.55%)    10 (38.46%)   15 (57.70%)    1(3.84%)      16 (61.54)     69/17     25/17
  Zhu                           56/102                     6 (10.71%)              27 (48.21%)           23 (41.08%)   50 (89.29%)    20 (19.61)    57 (55.88%)    25 (24.51%)   82 (80.39%)    39/97     73/107
  Storti                        103/200                    27 (26%)                53 (52%)              23 (22%)      76 (74%)       52 (26%)      108 (54%)      40 (20%)      148 (74%)      107/212   99/188
  Sanchez-Urbina                60/62                      8 (13.3%)               38 (63.3%)            14 (23.3%)    52 (86.6%)     13 (21%)      37 (59.7%)     12 (19.3%)    49 (79%)       54/63     66/61
  Wang                          104/208                    25 (24.04%)             60 (57.69%)           19 (18.27%)   79 (76.39%)    49 (23.56%)   120 (57.69%)   39 (18.75%)   159 (76.44%)   110/218   98/198
  Li                            183/102                    32 (17.49%)             90 (49.18%)           61 (33.33%)   151 (82.51%)   20 (19.61%)   57 (55.88%)    25 (24.51%)   82 (80.39%)    154/97    212/107
  Peng                          91/101                     32 (35.2%)              48 (52.7%)            11 (12.1%)    59 (64.8%)     46 (45.5%)    44 (43.6%)     11 (10.9%)    55 (54.5%)     112/136   70/66
                                                                                                                                                                                                          
  *MTHFR* 1298AC polymorphism                              AA                      AC                    CC            AC + CC        AA            AC             CC            AC + CC        A         C
  Božovic                       52/55                      21 (40%)                27 (52%)              4 (8%)        31 (60%)       27 (49%)      27 (49%)       1 (2%)        28 (51%)       69/81     35/29
  van Driel                     230/251                    104 (45%)               102 (45%)             24 (10%)      126 (55%)      116 (46%)     104 (42%)      31 (12%)      135 (54%)      310/336   150/166
  Galdieri                      47/26                      26 (55.32%)             17 (36.17%)           4 (8.51%)     21 (44.68%)    15 (57.7%)    10 (38.46%)    1 (3.84%)     11 (42.3%)     69/25     25/12
  Storti                        103/200                    49 (48%)                46 (45%)              8 (7%)        54 (52%)       101 (50%)     86 (43%)       13 (7%)       99 (50%)       144/288   62/112

###### 

Genotype and allele distributions of fetal MTHFR C677T/A1298C polymorphisms in case--control studies included.

  Study                         Sample size case/control   Genotype distribution   Allele distribution                                                                                                     
  ----------------------------- -------------------------- ----------------------- --------------------- ------------- -------------- -------------- -------------- ------------- -------------- --------- ---------
  *MTHFR* 677CT polymorphism                               CC                      CT                    TT            CT + TT        CC             CT             TT            CT + TT        C         T
  Božovic                       54/58                      20 (37%)                28 (52%)              6 (11%)       34 (63%)       25 (43%)       26 (45%)       7 (12%)       33 (57%)       68/76     40/40
  García-Fragoso                27/220                     9 (33%)                 14 (52%)              4 (15%)       28 (67%)       84 (38%)       115 (52%)      21 (10%)      136 (62%)      32/283    22/157
  Xu                            502/527                    162 (32.2%)             244 (48.6%)           96 (19.1%)    340 (67.7%)    151 (28.7%)    261 (49.5%)    115 (21.8%)   376 (71.3%)    568/563   436/491
  Li                            104/208                    16 (15.38%)             42 (40.38%)           46 (44.24%)   88 (84.62%)    55 (26.44%)    114 (54.81%)   39 (18.75%)   153 (73.56%)   74/224    134/192
  van Driel                     229/251                    99 (43%)                103 (45%)             27 (12%)      130 (57%)      119 (47%)      107 (43%)      25 (10%)      132 (53%)      301/345   157/157
  Galdieri                      58/38                      30 (51.72%)             21 (36.21%)           7 (12.07%)    28 (48.28%)    18 (47.37%)    14 (36.84%)    6 (15.79%)    20 (52.63%)    81/50     35/26
  Zhu                           56/103                     7 (12.5%)               22 (39.28%)           27 (48.21%)   49 (87.49%)    22 (21.4%)     57 (55.3%)     24 (23.3%)    81 (78.6%)     36/101    76/105
  Lee                           213/195                    110 (51.64%)            89 (41.78%)           14 (6.57%)    103 (48.35%)   114 (58.46%)   68 (34.87%)    13 (6.67%)    81 (41.54%)    309/296   117/94
  Shaw                          151/428                    67 (44.37%)             68 (45.03%)           16 (10.6%)    84 (55.63%)    177 (41.36%)   199 (46.5%)    52 (12.14%)   251 (58.64%)   202/553   100303
  Storti                        103/200                    28 (27%)                55 (53%)              20 (20%)      75 (73%)       52 (26%)       108 (54%)      40 (20%)      148 (74%)      111/212   95/188
  Junker                        114/228                    51 (44.7%)              42 (36.8%)            21 (18.4%)    63 (55.2%)     129 (56.6%)    78 (34.2%)     21 (9.2%)     99 (43.4%)     144/336   84/120
  Sanchez-Urbina                60/62                      7 (11.7%)               41 (68.3%)            12 (20%)      53 (88.3%)     9 (14.5%)      46 (74.2%)     7 (11.3%)     53 (85.5%)     55/64     65/60
  Yan                           174/103                    28 (16.1%)              89 (51.14%)           57 (32.76%)   146 (83.9%)    22 (21.36%)    57 (55.34%)    24 (23.3%)    81 (78.64%)    145/101   203/105
  Gong                          244/136                    45 (18.4%)              123 (50.4%)           76 (31.1%)    199 (81.5%)    43 (31.6%)     72 (52.9%)     21 (15.4%)    93 (68.3%)     213/158   275/114
  Wang                          104/208                    16 (15.38%)             42 (40.38%)           39 (18.75%)   81 (59.13%)    55 (26.44%)    114 (54.81%)   39 (18.75%)   153 (73.56%)   74/224    120/192
  Li                            144/168                    26 (18.06%)             52 (36.11%)           66 (45.83%)   118 (81.94%)   49 (29.17%)    84 (50%)       35 (20.83%)   119 (70.83%)   104/182   184/154
  Gong                          80/80                      10 (12.5%)              41 (51.3%)            29 (36.3%)    70 (87.6%)     17 (21.3%)     40 (50%)       23 (28.8%)    63 (78.8%)     61/74     99/86
  Liu                           97/118                     19 (19.6%)              54 (55.7%)            24 (24.7%)    78 (80.4%)     33 (27.9%)     69 (58.5%)     16 (13.6%)    85 (72.1%)     92/135    102/101
  Li                            183/103                    30 (16.4%)              95 (51.91%)           58 (31.69%)   153 (83.6%)    22 (21.36%)    57 (55.34%)    24 (23.3%)    81 (78.64%)    155/101   211/105
                                                                                                                                                                                                           
  *MTHFR* 1298AC polymorphism                              AA                      AC                    CC            AC + CC        AA             AC             CC            AC + CC        A         C
  Božovic                       54/58                      30 (55%)                22 (41%)              2 (4%)        24 (45%)       25 (43%)       30 (52%)       3 (5%)        33 (57%)       82/80     26/36
  Xu                            502/527                    316 (62.9%)             168 (33.5%)           18 (3.6%)     186 (37.1%)    326 (61.9%)    185 (35.1%)    16 (3%)       201 (38.1%)    800/837   204/217
  van Driel                     229/251                    112 (49%)               90 (39%)              27 (12%)      117 (51%)      97 (39%)       129 (51%)      25 (10%)      154 (61%)      314/323   144/179
  Galdieri                      57/38                      35 (61.40%)             21 (36.84%)           1 (1.76%)     22 (38.6%)     19 (50%)       16 (42.11%)    3 (7.89%)     19 (50%)       91/54     23/22
  Storti                        103/200                    45 (43%)                47 (46%)              11 (11%)      58 (57%)       101 (50%)      86 (43%)       13 (7%)       99 (50%)       137/288   69/112

###### 

Pooled ORs and 95% CIs of the association between maternal MTHFR C677T polymorphism and CHD.

  Contrasts              No. of studies   Total case/control   T vs. C   TT vs. CC      TT + CT vs. CC   TT vs. TC + CC                                                                                
  ---------------------- ---------------- -------------------- --------- -------------- ---------------- ---------------- -------------- ------- ------- -------------- ------- ------- -------------- -------
  All                    14               1745/2044            1.103     0.999--1.218   0.018            1.254            1.012--1.553   0.167   1.105   0.958--1.275   0.220   1.235   1.024--1.489   0.098
  Study in HWE           12               1523/1515            1.098     0.984--1.224   0.007            1.247            0.986--1.578   0.104   1.092   0.935--1.275   0.130   1.244   1.012--1.528   0.076
                                                                                                                                                                                                       
  *Ethnicity*                                                                                                                                                                                          
  Caucasian              10               1311/1531            1.062     0.945--1.193   0.014            1.189            0.925--1.527   0.121   1.067   0.909--1.251   0.145   1.165   0.926--1.466   0.066
  Asian                  4                434/513              1.204     0.973--1.490   0.175            1.454            0.921--2.295   0.207   1.170   0.802--1.707   0.438   1.431   1.011--2.024   0.228
                                                                                                                                                                                                       
  *Types of CHD*                                                                                                                                                                                       
  All types              11               1586/1742            1.072     0.960--1.197   0.016            1.202            0.947--1.525   0.140   1.071   0.917--1.250   0.197   1.192   0.964--1.474   0.067
  CD                     1                103/200              1.043     0.745--1.461   --               1.107            0.554--2.213   --      0.989   0.576--1.699   --      1.150   0.645--2.052   --
  ASD/PDA                1                56/102               1.697     1.054--2.731   --               3.067            1.048--8.974   --      2.033   0.765--5.403   --      2.147   1.068--4.314   --
                                                                                                                                                                                                       
  *Source of controls*                                                                                                                                                                                 
  HB                     6                514/750              1.092     0.883--1.351   0.004            1.504            0.999--2.264   0.120   0.952   0.701--1.293   0.156   1.550   1.106--2.170   0.099
  PB                     6                1175/1192            1.060     0.936--1.201   0.573            1.078            0.823--1.412   0.500   1.090   0.914--1.300   0.135   1.028   0.803--1.318   0.500
                                                                                                                                                                                                       
  *Sample size*                                                                                                                                                                                        
  Small                  6                1441/1486            1.081     0.963--1.214   0.884            1.110            0.865--1.425   0.672   1.115   0.947--1.314   0.977   1.090   0.874--1.361   0.333
  Large                  7                304/558              1.136     0.913--1.412   0.001            1.854            1.161--2.961   0.090   0.953   0.682--1.331   0.034   1.838   1.252--2.700   0.199

Abbreviations: OR, odds ratio; CI, confidence interval; *P*~H~, p value based on Q test for between-study heterogeneity; HWE, Hardy--Weinberg equilibrium; CD, conotruncal heart defects; ASD, atrial septal defect; PDA, patent ductus arteriosus; PB, population-based; HB, hospital-based.

###### 

Pooled ORs and 95% CIs of the association between fetal MTHFR C677T polymorphism and CHD.

  Contrasts              No. of studies   Total case/control   T vs. C   TT vs. CC      TT + CT vs. CC   TT vs. TC + CC                                                                                
  ---------------------- ---------------- -------------------- --------- -------------- ---------------- ---------------- -------------- ------- ------- -------------- ------- ------- -------------- -------
  All                    19               2697/3434            1.271     1.178--1.372   0.000            1.610            1.374--1.885   0.000   1.258   1.120--1.414   0.057   1.565   1.370--1.788   0.000
  Study in HWE           17               2657/3006            1.247     1.155--1.348   0.000            1.537            1.308--1.807   0.000   1.238   1.101--1.392   0.070   1.492   1.302--1.711   0.000
                                                                                                                                                                                                       
  *Ethnicity*                                                                                                                                                                                          
  Caucasian              8                796/1485             1.108     0.970--1.264   0.252            1.233            0.925--1.643   0.296   1.151   0.956--1.385   0.444   1.196   0.920--1.556   0.399
  Asian                  11               1901/1949            1.358     1.240--1.487   0.000            1.793            1.487--2.162   0.000   1.345   1.164--1.555   0.042   1.695   1.455--1.976   0.000
                                                                                                                                                                                                       
  *Types of CHD*                                                                                                                                                                                       
  All types              15               2197/2877            1.233     1.136--1.339   0.000            1.496            1.259--1.777   0.000   1.230   1.087--1.391   0.099   1.474   1.274--1.707   0.000
  CD                     3                444/454              1.391     1.148--1.686   0.026            2.053            1.371--3.075   0.021   1.471   1.074--2.015   0.106   1.751   1.249--2.455   0.059
  ASD/PDA                1                56/103               2.031     1.255--3.287   --               3.536            1.284--9.735   --      1.901   0.757--4.778   --      3.065   1.529--6.142   --
                                                                                                                                                                                                       
  *Source of controls*                                                                                                                                                                                 
  HB                     12               1850/2201            1.322     1.208--1.448   0.000            1.720            1.431--2.067   0.000   1.323   1.146--1.526   0.021   1.633   1.401--1.904   0.000
  PB                     5                677/902              1.101     0.945--1.283   0.509            1.225            0.871--1.723   0.488   1.101   0.881--1.376   0.688   1.215   0.902--1.638   0.542
                                                                                                                                                                                                       
  *Sample size*                                                                                                                                                                                        
  Small                  7                432/679              1.332     1.134--1.565   0.537            1.877            1.294--2.722   0.570   1.501   1.147--1.964   0.875   1.655   1.224--2.237   0.390
  Large                  12               2265/2755            1.254     1.154--1.363   0.000            1.551            1.306--1.843   0.000   1.221   1.077--1.385   0.013   1.531   1.323--1.772   0.000

Abbreviations: OR, odds ratio; CI, confidence interval; *P*~H~, p value based on Q test for between-study heterogeneity; HWE, Hardy--Weinberg equilibrium; CD, conotruncal heart defects; ASD, atrial septal defect; PDA, patent ductus arteriosus; PB, population-based; HB, hospital-based

###### 

Pooled ORs and 95% CIs of the association between maternal/fetal MTHFR A1298C polymorphism and CHD.

  Contrasts          No. of studies   Total case/control   C vs. A   CC vs. AA      CC + AC vs. AA   CC vs. AC + AA                                                                                  
  ------------------ ---------------- -------------------- --------- -------------- ---------------- ---------------- --------------- ------- ------- -------------- ------- ------- --------------- -------
  *Maternal*                                                                                                                                                                                         
  All studies        4                432/532              1.043     0.855--1.271   0.585            1.109            0.692--1.775    0.405   1.108   0.856--1.435   0.912   0.735   0.467--1.157    0.053
  All types of CHD   3                329/332              1.018     0.805--1.287   0.407            1.062            0.617--1.825    0.250   1.102   0.810--1.499   0.769   0.615   0.366--1.034    0.063
  CD                 1                103/200              1.107     0.765--1.601   --               1.268            0.493--3.262    --      1.124   0.699--1.809   --      1.276   0.512--3.183    --
  HB                 2                150/226              1.040     0.741--1.458   0.407            1.405            0.594--3.323    0.634   1.120   0.731--1.716   0.970   1.412   0.613--3.253    0.627
  PB                 2                282/306              1.044     0.818--1.344   0.263            1.003            0.572--1.761    0.134   1.102   0.796--1.524   0.468   0.557   0.324--0.957    0.048
  Small              2                99/81                1.150     0.712--1.856   0.224            3.476            0.700--17.271   0.625   1.289   0.708--2.350   0.684   3.266   0.674--15.825   0.682
  Large              2                333/451              1.022     0.822--1.270   0.599            0.961            0.581--1.591    0.500   1.071   0.804--1.426   0.800   0.608   0.372--0.993    0.059
                                                                                                                                                                                                     
  *Fetal*                                                                                                                                                                                            
  All studies        5                945/1074             0.938     0.812--1.083   0.171            1.058            0.719--1.558    0.331   0.871   0.728--1.042   0.128   1.184   0.815--1.721    0.516
  All types of CHD   4                842/874              0.884     0.756--1.034   0.422            0.924            0.600--1.421    0.460   0.813   0.670--0.987   0.281   1.085   0.715--1.646    0.496
  CD                 1                103/200              1.295     0.901--1.861   --               1.899            0.791--4.562    --      1.315   0.815--2.121   --      1.720   0.742--3.987    --
  HB                 3                662/765              1.017     0.851--1.216   0.145            1.221            0.725--2.057    0.168   0.991   0.799--1.229   0.275   1.216   0.729--2.027    0.233
  PB                 2                283/309              0.805     0.630--1.028   0.627            0.889            0.499--1.582    0.603   0.648   0.467--0.898   0.846   1.149   0.664--1.989    0.582
  Small              2                111/96               0.667     0.428--1.041   0.781            0.351            0.084--1.460    0.461   0.616   0.354--1.073   0.949   0.427   0.105--1.730    0.416
  Large              3                834/978              0.976     0.838--1.136   0.150            1.166            0.778--1.749    0.429   0.907   0.750--1.096   0.064   1.293   0.875--1.912    0.758
  Caucasian          4                443/547              0.902     0.743--1.095   0.108            1.014            0.636--1.618    0.209   0.793   0.615--1.023   0.106   1.183   0.757--1.848    0.353
  Asian              1                502/527              0.984     0.794--1.219   --               1.161            0.582--2.316    --      0.955   0.742--1.229   --      1.188   0.599--2.356    --

Abbreviations: OR, odds ratio; CI, confidence interval; *P*~H~, p value based on Q test for between-study heterogeneity; HWE, Hardy--Weinberg equilibrium; CD, conotruncal heart defects; PB, population-based; HB, hospital-based.
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